Article
Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens.
Journal of clinical microbiology - 1 Jun 2009
Hillemann Doris, Rüsch-Gerdes Sabine, Richter Elvira
Abstract excerpt
The new GenoType Mycobacterium tuberculosis drug resistance second line (MTBDRsl) assay (Hain Lifescience, Nehren, Germany) was tested on 106 clinical isolates and directly on 64 sputum specimens for the ability to detect resistance to fluoroquinolones, injectable drugs (amikacin or capreomycin), and ethambutol in Mycobacterium tuberculosis strains. A total of 63 strains harboring fluoroquinolone,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
